Genmab Deal History & Licensing Activity
Genmab is a large biotech headquartered in Denmark. Over the past three years, Genmab has been involved in 5 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (3 deals). The company currently has 50 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
1
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Hematological Malignancies
Genmab Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Genmab in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Merus antibody pipeline | Merus N.V. | Bispecific Antibodies | Unknown | acquisition | May 2026 |
Genmab Pipeline Focus
Therapeutic areas and modalities where Genmab is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Genmab Strategic Signals
Key indicators of Genmab's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Genmab Clinical Pipeline
Genmab has 50 active clinical trials across 5 development phases.
1
Phase 4
1
Unknown
20
Phase 1
18
Phase 2
10
Phase 3
See How Your Asset Matches Genmab's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Genmab Licensing & Deal Activity
Genmab is a large biotech company based in Denmark that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Genmab ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Genmab include Hematological Malignancies (25 deals and trials), Solid Tumors (13 deals and trials), Mega Deals (2 deals and trials), and Option Deals (2 deals and trials). In terms of modality, Genmab has shown particular interest in bispecific antibodies, adc, car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Genmab and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Genmab's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.